RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=35922919
Also from the March 07, 2024 "State of Union" address the Biden administration is also looking to expand the $2,000 cap on out-of-pocket spending for prescription drugs, which will apply to senior beneficiaries of Medicare by 2025.
This move will add further incentive to the use of biologics like ONCY's pelareorep in combination with other oncology agents, like checkpoint inhibitors, small molecules (i.e. PARP,CDK4 inhibitors), gene and cell therapies (i.e. CAR-T therapy), bispecifics and antibody drug conjugates (ADCs), for example.
And since the Biden administration is looking to cap cost-sharing for certain generic drugs, Big Pharma will be looking to move away from the development of small molecule drugs because the IRA will only offer them 9 years of market exclusivity before they become genericized. So there is added incentive for Big Pharma to develop biological agents in the treatment of multiple disease states OR acquire biotech companies like ONCY that is developing the biologic pelareorep for multiple cancers, like pancreatic, breast, anal, colorectal, ovarian and GI cancers.
https://www.biospace.com/article/biden-calls-for-expanding-ira-s-drug-price-negotiation-program/